Quinterol Mallette Appointed To GenVec Inc. Board Of Directors
GAITHERSBURG, Md., Oct. 31, 2014 /PRNewswire/ -- GenVec, Inc. (NASDAQ: GNVC) today announced that the Board of Directors of GenVec, Inc. appointed Quinterol J. Mallette, M.D. as a director of the company. In addition, Dr. Mallette was appointed to the board's audit committee.
Dr. Mallette is currently a Senior Analyst at SWK Holdings, Inc., a publically-traded health care-focused specialty finance firm, a position he has held since 2013. From 2011 to 2013, he was the founder and president of Mallette Research Associates, a provider of in-depth, real-time equity research to brokerage houses. From 2009 to 2011, Dr. Mallette was the founder and president of the Invictus Trading Group, Inc., a proprietary trading group focused on the health care space. Dr. Mallette began his career in 2001 at Lehman Brothers as an equity research analyst covering the biotechnology industry. Dr. Mallette left Lehman to fill the role of senior analyst for a health care-dedicated investment fund, before starting his own firm, Mallette Capital Management. Dr. Mallette holds a medical degree from Duke's School of Medicine and an MBA from the Fuqua School of Business. He also received BS degrees in Biomedical Engineering and Psychology from Duke University.
"Quin brings unique insight and perspective to the GenVec Board and we look forward to working with him and benefitting from his experience. His medical training and background in health care investing will serve the company well as we execute our plan to maximize the value of our technology platform," commented Douglas J. Swirsky, GenVec's President and CEO.
About GenVec
GenVec is a clinical-stage biopharmaceutical company focused on leveraging its adenovector gene delivery platform to develop a pipeline of cutting-edge therapeutics and vaccines. The company is a pioneer in the design, testing and manufacture of adenoviral-based product candidates that can deliver on the promise of gene-based medicine. Current GenVec partners and collaborators include leading organizations such as Novartis and the U.S. Government. The company also licenses its proprietary technology platform, including vectors and production cell lines, for the development and manufacture of therapeutics and vaccines to the biopharmaceutical industry. GenVec's lead program, in the field of regenerative medicine, is licensed to Novartis for the development of novel treatments for hearing loss and balance disorders. Additional information about GenVec is available at www.genvec.com and in the company's various filings with the Securities and Exchange Commission.
Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including with respect to the transition of GenVec's business focus are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. GenVec cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, such as the failure of Novartis to advance GenVec's hearing loss and balance disorders program. Further information on the factors and risks that could affect GenVec's business, financial conditions and results of operations, are contained in GenVec's filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. These forward-looking statements speak only as of the date of this press release, and GenVec assumes no duty to update forward-looking statements.
Contact:
GenVec, Inc.
Rena Cohen
(240) 632-5501
rcohen@genvec.com
SOURCE GenVec, Inc.